Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024

Report ID: BMRC 48 | Number of pages: 200 | Publish Date: May 2019 | Publisher: BMRC | Category: Chemicals and Materials
Global Thalassemia Treatment Market 2018-2024
Brandessence Market Research is working on a new report title“Global Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports –

 Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (ß4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports –

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics –

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.2±2.2. Average 18.5%±14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis –

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports –

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.
Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
Global Thalassemia Treatment Market report helps to identify opportunities in market place.
Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.
Global Thalassemia Treatment Market Segmentation–

 Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood Transfusion
Chelating Therapy
Bone Marrow Transplant
Stem Cell Transplant
Surgery
Gene Therapy
Other
Global Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal Testing
Prenatal Testing
Pre-Implantation
Other
Global Thalassemia Treatment Market: By End user Analysis

Hospitals
Biotechnological Laboratories
Diagnostic Laboratories
Educational Research Institutes
Pharmaceutical Industries
Other
Global Thalassemia Treatment Market: By Regional & Country Analysis

North America
U.S.
Mexico
Canada
Europe
UK
France
Germany
Italy
Asia Pacific
China
Japan
India
Southeast Asia
Latin America
Brazil
The Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Table of Content

Chapter – Report Methodology
Research Process
Primary Research
Secondary Research
Market Size Estimates
Data Triangulation
Forecast Model
USP’s of Report
Report Description
Chapter – Global Thalassemia Treatment Market Overview: Qualitative Analysis
Market Introduction
Executive Summary
Global Thalassemia Treatment Market Classification
Market Drivers
Market Restraints
Market Opportunity
Global Thalassemia Treatment Market: Trends
Porter’s Five Forces Analysis
Bargaining Power of Suppliers
Bargaining Power of Consumers
Threat of New Entrants
Threat of Substitute Product and Services
Competitive Rivalry within the Industry
Market Attractiveness Analysis
Market Attractiveness Analysis by Segmentation
Market Attractiveness Analysis by Region
Chapter – Global Thalassemia Treatment Market Overview: Quantitative Analysis
Global Thalassemia Treatment Market Production (K Unit), Market Share (%) and Growth Rate (%), 2014- 2024
Global Thalassemia Treatment Market Consumption (K Unit), Market Share ( %) and Growth Rate, 2014- 2024
Global Thalassemia Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate (%), 2014- 2024
Chapter –Global Thalassemia Treatment Market: by Type of Treatment
Chapter –Global Thalassemia Treatment Market: by Diagnosis
Chapter –Global Thalassemia Treatment Market: by End user
Chapter –Global Thalassemia Treatment Market: by Manufacturer
Global Thalassemia Treatment Market(USD Million), by Manufacturer, 2014 – 2024
Global Thalassemia Treatment Market Production (K Unit), by Manufacturer, 2014 – 2024
Global Thalassemia Treatment Market Consumption (K Unit), Manufacturer, 2014 – 2024
Global Thalassemia Treatment Market Share (%), by Manufacturer, 2017
Global Thalassemia Treatment Market Price (USD/Unit), by Manufacturer, 2014 – 2024
Global Thalassemia Treatment Market Revenue Growth Rate (%), by Manufacturer, 2014 – 2024
Merger & Acquisition
Collaborations and Partnership
New Product Launch
Chapter -Global Thalassemia Treatment Market: Regional Analysis
North America
North America Global Thalassemia Treatment Market Revenue (USD Million) and Growth Rate (%), 2014 – 2024.
North America Global Thalassemia Treatment Market Revenue (USD Million) By Country, 2014 – 2024.
North America Global Thalassemia Treatment Market Revenue Market Share (%) By Country, 2014 – 2024.
North America Global Thalassemia Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2024.
North America Global Thalassemia Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2024.
North AmericaGlobal Thalassemia Treatment Market Revenue (USD Million), Market Share (%) and Growth Rate, By Market Segmentation, 2014 – 2024.
Europe
Asia Pacific
Latin America
Middle East & Africa
Chapter – Company Profiles
8.1.1. Acceleron Pharma Inc.

8.1.2.Overview

8.1.3.Financials

Product portfolio
Global Thalassemia Treatment Market Revenue (USD Million), Production (K Unit), Consumption (K Unit) and Market Share (%), 2014 – 2017
Global Thalassemia Treatment Market Share (%), 2014 – 2017
Alnylam Pharmaceuticals Inc.
Bellicum Pharmaceuticals
Bluebird bio Inc.
Calimmune Inc.
Celgene Corporation
CRISPR Therapeutics
DiagCor Bioscience Inc. Ltd
Editas Medicine Inc.
Errant Gene Therapeutics LLC
Gamida Cell Ltd
Genorama Ltd
Gilead Sciences Inc.
GlaxoSmithKline Plc
HiMedia Laboratories
Incyte Corp
Ionis Pharmaceuticals Inc.
IRBM Science Park SpA
Johnson & Johnson
Kiadis Pharma NV
La Jolla Pharmaceutical Company
Lonza group
Merck & Co Inc.
Novartis AG
PharmaEssentia Corp
Protagonist Therapeutics Inc.
Sangamo Therapeutics Inc.
Shire plc
Tosoh Bioscience Inc.
Zydus Cadila Healthcare Ltd
Others
Chapter – Market Research and Findings
This free Sample Report is purely a representation of our full report, for evaluating the market scope/data and make informed purchase decisions.